Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands

Overview

Journal J Neuromuscul Dis

Publisher Sage Publications

Specialty Neurology

Date 2018 Feb 27

PMID 29480217

Citations 7

Authors

Maaike van Putten

Annemieke Aartsma-Rus

Miranda D Grounds

Joe N Kornegay

Anna Mayhew

Thomas H Gillingwater

Shinichi Takeda

Markus A Ruegg

Annamaria De Luca

Kanneboyina Nagaraju

Raffaella Willmann

Affiliations

Soon will be listed here.

Abstract

A workshop took place in 2015 to follow up TREAT-NMD activities dedicated to improving quality in the preclinical phase of drug development for neuromuscular diseases. In particular, this workshop adressed necessary future steps regarding common standard experimental protocols and the issue of improving the translatability of preclinical efficacy studies.

Citing Articles

Pharmacological Therapies of Spinal Muscular Atrophy: A Narrative Review of Preclinical, Clinical-Experimental, and Real-World Evidence.

Crisafulli S, Boccanegra B, Vitturi G, Trifiro G, De Luca A Brain Sci. 2023; 13(10).

PMID: 37891814 PMC: 10605203. DOI: 10.3390/brainsci13101446.

Navigating regulatory pathways for translation of biologic cartilage repair products.

Nordberg R, Otarola G, Wang D, Hu J, Athanasiou K Sci Transl Med. 2022; 14(659):eabp8163.

PMID: 36001677 PMC: 9918326. DOI: 10.1126/scitranslmed.abp8163.

The predictive value of models of neuromuscular disorders to potentiate clinical translation.

van Putten M Dis Model Mech. 2022; 15(7).

PMID: 35912512 PMC: 9366891. DOI: 10.1242/dmm.049788.

Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy.

Bourg N, Vu Hong A, Lostal W, Jaber A, Guerchet N, Tanniou G Int J Mol Sci. 2022; 23(4).

PMID: 35216132 PMC: 8878028. DOI: 10.3390/ijms23042016.

Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy.

Dort J, Orfi Z, Fabre P, Molina T, Conte T, Greffard K Nat Commun. 2021; 12(1):6264.

PMID: 34716330 PMC: 8556273. DOI: 10.1038/s41467-021-26516-0.

References

Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J . Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int. 2011; 17(2):101-9. DOI: 10.1002/pri.520. View

Mayhew A, Mazzone E, Eagle M, Duong T, Ash M, Decostre V . Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy. Dev Med Child Neurol. 2013; 55(11):1038-45. DOI: 10.1111/dmcn.12213. View

Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A . Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy. Lancet Neurol. 2016; 15(8):882-890. DOI: 10.1016/S1474-4422(16)30035-7. View

Mazzone E, Mayhew A, Montes J, Ramsey D, Fanelli L, Dunaway Young S . Revised upper limb module for spinal muscular atrophy: Development of a new module. Muscle Nerve. 2016; 55(6):869-874. DOI: 10.1002/mus.25430. View

McDonald C, Henricson E, Abresch R, Florence J, Eagle M, Gappmaier E . The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve. 2013; 48(3):343-56. PMC: 3824082. DOI: 10.1002/mus.23902. View

Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F . Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy. Dev Med Child Neurol. 2011; 53(6):535-42. DOI: 10.1111/j.1469-8749.2011.03939.x. View

Willmann R, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers J . Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord. 2011; 22(1):43-9. PMC: 3227750. DOI: 10.1016/j.nmd.2011.04.012. View

Yu X, Bao B, Echigoya Y, Yokota T . Dystrophin-deficient large animal models: translational research and exon skipping. Am J Transl Res. 2015; 7(8):1314-31. PMC: 4568789. View

Willmann R, Dubach J, Chen K . Developing standard procedures for pre-clinical efficacy studies in mouse models of spinal muscular atrophy: report of the expert workshop "Pre-clinical testing for SMA", Zürich, March 29-30th 2010. Neuromuscul Disord. 2010; 21(1):74-7. DOI: 10.1016/j.nmd.2010.09.014. View

10.

Glanzman A, Mazzone E, Main M, Pelliccioni M, Wood J, Swoboda K . The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. Neuromuscul Disord. 2010; 20(3):155-61. PMC: 3260046. DOI: 10.1016/j.nmd.2009.11.014. View

11.

Willmann R, De Luca A, Nagaraju K, Ruegg M . Best Practices and Standard Protocols as a Tool to Enhance Translation for Neuromuscular Disorders. J Neuromuscul Dis. 2016; 2(2):113-117. DOI: 10.3233/JND-140067. View

12.

Kornegay J, Bogan J, Bogan D, Childers M, Grange R . Golden retriever muscular dystrophy (GRMD): Developing and maintaining a colony and physiological functional measurements. Methods Mol Biol. 2011; 709:105-23. DOI: 10.1007/978-1-61737-982-6_7. View

13.

Heslop E, Csimma C, Straub V, McCall J, Nagaraju K, Wagner K . The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development. Orphanet J Rare Dis. 2015; 10:49. PMC: 4417237. DOI: 10.1186/s13023-015-0258-1. View

14.

Montes J, McDermott M, Martens W, Dunaway S, Glanzman A, Riley S . Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology. 2010; 74(10):833-8. PMC: 2839195. DOI: 10.1212/WNL.0b013e3181d3e308. View

15.

Schatzberg S, Olby N, Breen M, Anderson L, Langford C, Dickens H . Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul Disord. 1999; 9(5):289-95. DOI: 10.1016/s0960-8966(99)00011-5. View

16.

Atencia-Fernandez S, Shiel R, Mooney C, Nolan C . Muscular dystrophy in the Japanese Spitz: an inversion disrupts the DMD and RPGR genes. Anim Genet. 2015; 46(2):175-84. DOI: 10.1111/age.12266. View

17.

Glanzman A, OHagen J, McDermott M, Martens W, Flickinger J, Riley S . Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol. 2011; 26(12):1499-507. DOI: 10.1177/0883073811420294. View

18.

Grounds M, Radley H, Lynch G, Nagaraju K, De Luca A . Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008; 31(1):1-19. PMC: 2518169. DOI: 10.1016/j.nbd.2008.03.008. View

19.

Kornegay J, Bogan J, Bogan D, Childers M, Li J, Nghiem P . Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome. 2012; 23(1-2):85-108. PMC: 3911884. DOI: 10.1007/s00335-011-9382-y. View

20.

Ricotti V, Ridout D, Pane M, Main M, Mayhew A, Mercuri E . The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry. 2015; 87(2):149-55. PMC: 4752678. DOI: 10.1136/jnnp-2014-309405. View